Skip to content

Harrow HROW Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

AbbVie logo
AbbVieABBV
Viatris logo
ViatrisVTRS
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
PBH
Prestige Consumer HealthcarePBH
Organon logo
OrganonOGN
Warby Parker logo
Warby ParkerWRBY

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's common stock, shares authorized (in shares)?
Harrow (HROW) reported common stock, shares authorized (in shares) of $50M in Q1 2026.
How has Harrow's common stock, shares authorized (in shares) changed year-over-year?
Harrow's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $50M to $50M.
What is the long-term trend for Harrow's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Harrow's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $50M to $50M.